Cost-effectiveness of precision medicine: a scoping review.


Journal

International journal of public health
ISSN: 1661-8564
Titre abrégé: Int J Public Health
Pays: Switzerland
ID NLM: 101304551

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 25 05 2019
accepted: 04 09 2019
revised: 19 08 2019
pubmed: 28 10 2019
medline: 26 2 2020
entrez: 26 10 2019
Statut: ppublish

Résumé

Precision medicine (PM) aims to improve patient outcomes by stratifying or individualizing diagnosis and treatment decisions. Previous reviews found inconclusive evidence as to the cost-effectiveness of PM. The purpose of this scoping review was to describe current research findings on the cost-effectiveness of PM and to identify characteristics of cost-effective interventions. We searched PubMed with a combination of terms related to PM and economic evaluations and included studies published between 2014 and 2017. A total of 83 articles were included, of which two-thirds were published in Europe and the USA. The majority of studies concluded that the PM intervention was at least cost-effective compared to usual care. However, the willingness-to-pay thresholds varied widely. Key factors influencing cost-effectiveness included the prevalence of the genetic condition in the target population, costs of genetic testing and companion treatment and the probability of complications or mortality. This review may help inform decisions about reimbursement, research and development of PM interventions.

Identifiants

pubmed: 31650223
doi: 10.1007/s00038-019-01298-x
pii: 10.1007/s00038-019-01298-x
pmc: PMC6867980
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1261-1271

Références

Pharmacogenomics. 2015;16(10):1089-100
pubmed: 26230572
J Rheumatol. 2017 Jun;44(6):835-843
pubmed: 28365572
Epilepsia. 2015 Apr;56(4):556-63
pubmed: 26046144
Leuk Res. 2017 Nov;62:84-90
pubmed: 28988037
PLoS One. 2016 Jan 11;11(1):e0146262
pubmed: 26752539
Gynecol Oncol. 2016 Dec;143(3):453-459
pubmed: 27789085
Pharmacogenomics. 2016 Jun;17(9):985-94
pubmed: 27266545
J Natl Cancer Inst. 2015 Mar 20;107(4):null
pubmed: 25794514
Pharmacogenomics J. 2016 Oct;16(5):478-84
pubmed: 27272045
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Genet Med. 2008 Sep;10(9):648-54
pubmed: 18978674
Appl Health Econ Health Policy. 2015 Apr;13(2):233-42
pubmed: 25652150
Genet Med. 2016 Dec;18(12):1171-1180
pubmed: 27906166
Ann Ig. 2017 Sep-Oct;29(5):464-480
pubmed: 28715059
Clin Transl Sci. 2017 Mar;10(2):61-63
pubmed: 28083940
Pharmacoeconomics. 2010;28(11):1001-13
pubmed: 20936884
Pharmacogenet Genomics. 2014 Jan;24(1):6-14
pubmed: 24168919
Epidemiol Prev. 2015 Jul-Aug;39(4 Suppl 1):45-50
pubmed: 26499415
Pharmacoeconomics. 2014 May;32(5):443-55
pubmed: 24574059
Per Med. 2009 Mar;6(2):193-215
pubmed: 20668661
Lung Cancer. 2015 Oct;90(1):71-7
pubmed: 26259876
J Med Genet. 2017 Nov;54(11):747-753
pubmed: 28835481
Eur J Health Econ. 2017 Dec;18(9):1065-1067
pubmed: 28382502
Genet Med. 2014 Mar;16(3):251-7
pubmed: 24232413
Int J Retina Vitreous. 2015 Oct 26;1:19
pubmed: 27847612
Am J Manag Care. 2013 Dec;19(12):1024-31
pubmed: 24512037
Pharmgenomics Pers Med. 2015 Jun 24;8:115-26
pubmed: 26309416
Value Health. 2017 Apr;20(4):547-555
pubmed: 28407996
Appl Health Econ Health Policy. 2014 Apr;12(2):203-17
pubmed: 24595521
Surgery. 2018 Jan;163(1):88-96
pubmed: 29128178
Thromb Res. 2014 Dec;134(6):1278-84
pubmed: 25456732
BMC Health Serv Res. 2014 Sep 05;14:372
pubmed: 25190451
Pharmacogenomics J. 2018 May 22;18(3):391-397
pubmed: 28696420
Healthcare (Basel). 2015;3(4):860-78
pubmed: 26473097
EPMA J. 2015 Sep 30;6:19
pubmed: 26425215
PLoS One. 2016 Aug 02;11(8):e0160155
pubmed: 27483001
BMC Cancer. 2017 Oct 16;17(1):685
pubmed: 29037213
Clin Pharmacol Ther. 2008 Aug;84(2):179-82
pubmed: 18679176
Health Technol Assess. 2017 Sep;21(51):1-238
pubmed: 28895526
BMC Cancer. 2015 Apr 25;15:313
pubmed: 25910169
Pharmacogenomics. 2015 Dec;16(18):2007-18
pubmed: 26607811
Springerplus. 2015 Dec 01;4:752
pubmed: 26693110
J Thromb Thrombolysis. 2017 Nov;44(4):494-506
pubmed: 28918448
Value Health. 2015 Jul;18(5):700-8
pubmed: 26297099
J Natl Cancer Inst. 2014 Nov 30;107(1):380
pubmed: 25435542
BMJ Open. 2016 Jul 13;6(7):e010243
pubmed: 27412099
Med Decis Making. 2010 May-Jun;30(3):328-40
pubmed: 20086232
Int J Technol Assess Health Care. 2014 Apr;30(2):179-87
pubmed: 24806420
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 May;55(5):710-4
pubmed: 22526860
PLoS One. 2016 Aug 02;11(8):e0160599
pubmed: 27482709
BMC Cardiovasc Disord. 2015 Sep 29;15:104
pubmed: 26419225
Health Technol Assess. 2014 Sep;18(58):1-406
pubmed: 25244061
JRSM Cardiovasc Dis. 2012 Apr 05;1(1):null
pubmed: 24175062
Pharmacogenomics J. 2018 Jan;18(1):113-120
pubmed: 28117433
Diabetes Care. 2014;37(1):202-9
pubmed: 24026547
Pharmacoeconomics. 2016 Aug;34(8):771-93
pubmed: 26984520
Adv Ther. 2016 Sep;33(9):1461-80
pubmed: 27406232
Pharmacogenet Genomics. 2016 Aug;26(8):390-6
pubmed: 27195528
Clin Pharmacol Ther. 2017 Nov;102(5):739-741
pubmed: 28581028
AAPS PharmSci. 2000;2(3):E29
pubmed: 11741245
Pharmacoeconomics. 2015 Nov;33(11):1215-28
pubmed: 26081300
Gynecol Oncol. 2016 Jul;142(1):144-149
pubmed: 27106017
P R Health Sci J. 2017 Sep;36(3):165-172
pubmed: 28915306
J Clin Lipidol. 2014 Jul-Aug;8(4):390-400
pubmed: 25110220
Pharmacoeconomics. 2017 Aug;35(8):845-858
pubmed: 28762015
Pharm Pract (Granada). 2014 Jul;12(3):438
pubmed: 25243032
Pharmacogenomics. 2010 Nov;11(11):1573-90
pubmed: 21121811
Value Health. 2012 Dec;15(8):1162-71
pubmed: 23244820
Pharmacogenomics J. 2017 Oct;17(5):395-402
pubmed: 28607506
Pharmacogenomics. 2015 Nov;16(16):1781-93
pubmed: 26554739
Surgery. 2014 Dec;156(6):1569-77; discussion 1577-8
pubmed: 25444226
Pharmacogenomics J. 2016 Apr;16(2):129-36
pubmed: 25987241
Clin Pharmacol Ther. 2014 Feb;95(2):199-207
pubmed: 24067746
Value Health. 2017 Feb;20(2):213-216
pubmed: 28237197
JAMA. 2001 Oct 3;286(13):1637-8
pubmed: 11585493
Curr Treat Options Oncol. 2011 Mar;12(1):1-11
pubmed: 21267683
PLoS One. 2014 Apr 14;9(4):e94294
pubmed: 24732692
J Clin Lipidol. 2017 Jan - Feb;11(1):260-271
pubmed: 28391894
J Clin Oncol. 2015 Jun 20;33(18):2084-91
pubmed: 25940718

Auteurs

Miriam Kasztura (M)

Department of Health Professions, Bern University of Applied Sciences, Bern, Switzerland. mkasztura@gmail.com.

Aude Richard (A)

Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Nefti-Eboni Bempong (NE)

Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Dejan Loncar (D)

Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Antoine Flahault (A)

Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH